Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 260

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma

Open access
Verhoest, Grégory, Dolley-Hitze, Thibault, Jouan, Florence, Belaud-Rotureau, Marc-Antoine, Oger, Emmanuel, Lavenu, Audrey, Bensalah, Karim, Arlot-Bonnemains, Yannick, Collet, Nicolas, Rioux-Leclercq, Nathalie, Vigneau, Cécile·2014·BioMed Research International

Abstract

Background. Angiotensin-2 type-1 receptor antagonists not are only antihypertensive drugs but also can inhibit VEGF production. We hypothesised that adding telmisartan to sunitinib could potentiate the antiangiogenic effects.Material and Methods. 786-O cell lines were injected in nude mice. After tumor development, mice were divided into 4 groups: the first was the control group (DMSO), the second group was treated with sunitinib alone, the third group was treated with telmisartan alone, and the fourth group was treated with the combination. Drugs were orally administered every day for four weeks. Animals were sacrificed after treatment. Blood and tumor tissues were collected for analysis by immunohistochemistry, Western Blot, and ELISA methods.Results. All animals developed a ccRCC and ten in each group were treated. Using a kinetic model, tumors tended to grow slower in the combination group compared to others (P=0.06). Compared to sunitinib alone, the addition of telmisartan significantly increased tissue necrosis (P=0.038). Central microvascular density decreased (P=0.0038) as well as circulating VEGF (P=0.003). There was no significant variation in proliferation or apoptosis markers.Conclusion. The combination of sunitinib and telmisartan revealed an enhancement of the blockage of the VEGF pathway on renal tumor resulting in a decrease in neoangiogenesis and an increase in necrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2014/901371

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 260

Metadata

Authors
Verhoest, G., Dolley-Hitze, T., Jouan, F., Belaud-Rotureau, M.-A., Oger, E., Lavenu, A., Bensalah, K., Arlot-Bonnemains, Y., Collet, N., Rioux-Leclercq, N., & Vigneau, C.
Venue
BioMed Research International
Publisher
Wiley
Published
2014
Volume
2014
Pages
1-9
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
OpenAlex
W2123285648
Cited by
260
References
24
FWCI
23.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1155/2014/901371
The paper
Verhoest, G., Dolley-Hitze, T., Jouan, F., Belaud-Rotureau, M.-A., Oger, E., Lavenu, A., Bensalah, K., Arlot-Bonnemains, Y., Collet, N., Rioux-Leclercq, N., & Vigneau, C. (2014). Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma. BioMed Research International. https://doi.org/10.1155/2014/901371

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.